Asahi Kasei pays $15 million to Auxilium for rights to Dupuytren's, Peyronie's drug
This article was originally published in Scrip
Executive Summary
Tokyo-based Asahi Kasei Pharma is paying Auxilium Pharmaceuticals $15 million up front for the Japanese rights to develop, commercialize and supply Xiaflex (collagenase clostridium histolyticum) as a treatment for two rare progressive collagen deposit conditions, known as Dupuytren's contracture and Peyronie's disease.